Abstract 4021: The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations

2016 ◽  
Author(s):  
David Briere ◽  
Niranjan Sudhakar ◽  
Lars Engstrom ◽  
Jill Hallin ◽  
Ruth Tang ◽  
...  
Keyword(s):  
Antigen Presentation ◽  
Tumor Antigen ◽  
Immune Checkpoint ◽  
Hdac Inhibitor ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Class I

scholarly journals HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

2020 ◽  
Vol 11 (14) ◽  
pp. 4059-4072 ◽  
Author(s):  
Young-Dae Kim ◽  
Sang-Min Park ◽  
Hae Chan Ha ◽  
A Reum Lee ◽  
Heeyoung Won ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Hdac Inhibitor ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Immune Microenvironment ◽  
Anti Cancer

759 IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-156
Author(s):  
Yousef R. Badran ◽  
Angela Shih ◽  
Donna Leet ◽  
Alexandra Coromilas ◽  
Jonathan Chen ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor

Abstract #514 Secondary Adrenal Insufficiency Due to the Immune Checkpoint Inhibitor Pembrolizumab

2019 ◽  
Vol 25 ◽  
pp. 256
Author(s):  
Mohammad Ansari ◽  
Ula Tarabichi ◽  
Hadoun Jabri ◽  
Qiang Nai ◽  
Anis Rehman ◽  
...  
Keyword(s):  
Adrenal Insufficiency ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Secondary Adrenal Insufficiency
Sign in / Sign up

Export Citation Format

Share Document